Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProZema
- Development stage
- Unknown
- Lead developer
- ADM Biopolis
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ProZema is an oral live biotherapeutic product (LBP) consisting of a specific mixture of three probiotic bacterial strains: *Bifidobacterium lactis* CECT 8145, *Bifidobacterium longum* CECT 7347, and *Lactobacillus casei* CECT 9104. Developed by Biopolis (a subsidiary of Archer Daniels Midland), this microbial therapy is designed to modulate the gut-skin axis for the treatment of atopic dermatitis (eczema). The individual strains were selected for their specific functional properties: *B. lactis* CECT 8145 for its antioxidant activity, *B. longum* CECT 7347 for its anti-inflammatory effects, and *L. casei* CECT 9104 for complementary gut health benefits. Clinical evidence from randomized, double-blind, placebo-controlled trials in children and adolescents (ages 4-17) demonstrates that the mixture significantly reduces disease severity as measured by the SCORAD index and decreases the frequency and amount of topical corticosteroid use required to manage flares.
- Brand names
- ProZema
- Other names
- Bifidobacterium lactis CECT 8145 + Bifidobacterium longum CECT 7347 + Lactobacillus casei CECT 9104Biopolis probiotic mixtureADM probiotic blend
Beyond the preview
Go deeper on ProZema.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProZema.